Nivolumab Biosimilar(BioGenomics)

纳武利尤单抗生物类似药（BioGenomics）

Report date: 2025/02/20 10:08:15

Base Information

Drug NameNivolumab Biosimilar(BioGenomics)
Drug Alias NameNIVELUMABOpdiva BiosimilarOpdivo Biosimilar
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiogenomics
China Registration ClassN/A

Develop Information

Active CompaniesBiogenomics
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A